Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Owens v. Auxilium Pharmaceuticals, Inc.

United States Court of Appeals, Seventh Circuit

July 19, 2018

Isaac Owens, Plaintiff-Appellant,
v.
Auxilium Pharmaceuticals, Inc., Defendant-Appellee.

          Argued May 15, 2018

          Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 14 C 5180 - Matthew F. Kennelly, Judge.

          Before Bauer, Kanne, and Hamilton, Circuit Judges.

          Kanne, Circuit Judge.

         Isaac Owens used Testim, a topical gel containing 1% testosterone, sporadically for two years. During this time, he developed deep vein thrombosis. He sued Testim's manufacturer, alleging that the drug caused the condition. To show causation-a necessary element of all of his claims-Owens planned to rely on the testimony of Dr. Jihad Abbas. The district court excluded Dr. Abbas's testimony and, as a result, granted summary judgment in favor of the drug manufacturer. Owens appeals the district court's decision to exclude his expert's testimony and grant summary judgment. We affirm.

         I. Background

         Owens developed deep vein thrombosis ("DVT") while using Testim, a drug manufactured by the defendant-Auxilium Pharmaceuticals, LLC. He and other plaintiffs in a multi-district litigation allege that they suffered injuries because they took Testim and other testosterone-replacement-therapy drugs. Owens's case was selected for a bellwether trial in the multidistrict litigation.

         Owens began using Testim in July 2011 when his doctor diagnosed him with hypogonadism. Between July 2011 and July 2013, Owens used the drug sporadically. He refilled his prescription only three times, so he did not have enough of the drug to take a full daily dose during the time period. When Owens did use Testim, he did so incorrectly. Although the medication guide directs users to apply a full tube of Testim to the shoulders and arms, Owens testified that he would apply part of a tube to his thighs and stomach.

         On July 12, 2013, Owens was admitted to a hospital's emergency department for pain in his left leg. After an ultrasound revealed blood clots in his leg, he was diagnosed with DVT. Owens was treated with blood thinners and released from the hospital the following day.

         In his suit, Owens alleges that Testim caused the DVT and asserts claims for strict liability, negligence, fraud, and negligent misrepresentation under Kentucky law. Each of these claims requires expert testimony to establish causation. In re Testosterone Replacement Therapy Prod. Liab. Litig. Coordinated Pretrial Proceedings, No. 14 C 1748, 2017 WL 4772759, at *6 (N.D. Ill. Oct. 23, 2017) (citing Adams v. Cooper Indus., Inc., No. CIV.A. 03-476-JBC, 2012 WL 2339741, at *1 (E.D. Ky. June 19, 2012)). For that, Owens planned to rely on the testimony of Dr. Abbas. But Dr. Abbas's testimony was problematic. Although Dr. Abbas opined that Testim had caused Owens's DVT, he did so on the assumption that Owens was applying the prescribed dose of the gel in the proper manner. Moreover, when asked during his deposition about hypothetical cases that resembled Owens's use of Testim, Dr. Abbas explained that he had no opinion.

         Auxilium moved to exclude Dr. Abbas's testimony because it was not tied to the facts of the case. It also moved for summary judgment because, without the expert testimony, Owens could not show that Testim caused his injury. The district court agreed and granted summary judgment to Auxilium. Owens appealed.

         II. Analysis

         This appeal centers on the district court's exclusion of Dr. Abbas's testimony, which Owens argues was improper. Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) govern this decision. In relevant part, they require that the expert's testimony "assist the trier of fact." Ammons v. Aramark Unif. Servs., Inc., 368 F.3d 809, 816 (7th Cir. 2004) (quoting NutraSweet Co. v. X-L Eng'g Co., 227 F.3d 776, 788 (7th Cir. 2000)). To do so, the testimony must "fit the issue to which the expert is testifying and be tied to the facts of the case." Hartman v. EBSCO Indus., Inc., 758 F.3d 810, 819 (7th Cir. 2014) (quoting Deimer v. Cincinnati SubZero Prods., Inc., 58 F.3d 341, 345 (7th Cir. 1995)). When there is no question that the district court properly followed Daubert's framework-as is the case here-we consider whether the district court abused its discretion by excluding the testimony. Durkin v. Equifax Check Servs., Inc., 406 F.3d 410, 420 (7th Cir. 2005).

         Here, the district court properly exercised its discretion by concluding that Dr. Abbas's testimony did not fit the facts of Owens's case. Dr. Abbas testified that Testim caused Owens's DVT on the assumption that Owens used Testim as prescribed. This in fact was not the case. Owens instead testified that he used far less than the prescribed dose and that he did not apply the medication as directed. When presented hypotheticals that more closely resembled the facts of Owens's case, Dr. Abbas conceded that he could not offer an opinion. Because Dr. Abbas's testimony did not fit the facts of the case, it was not likely ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.